




Anaesthesia for TIPSS

- The Procedure
- Patient Selection
- Conduct of anaesthesia
- Potential Complications

Experience of TIPSS







Portal Hypertension

Pre-hepatic

Portal vein thrombosis

Splenic vein thrombosis

Intra-hepatic

Alcoholic cirrhosis

90% of cases in the Western World

Non-alcoholic fatty liver disease (NAFLD)

Viral hepatitis B and C

Drugs (e.g. methotrexate)

Wilson's disease

Haemochromatosis

Primary biliary cirrhosis

Sarcoidosis

Polycystic liver disease

Idiopathic fibrosis

Post-hepatic


Hepatic venous obstruction

Budd-Chiari syndrome

Portal Hypertension

- Significant impact on patient outcome and survival
- Clinically challenging and costly to manage
- Recurrent admissions and treatment for complications of portal hypertension
- TIPSS offers the minimally invasive option to lower portal pressure, provide symptom relief and confer survival benefit in selected patients

19



Hepatic Venous Pressure Gradient

- Normal HVPG is up to 5 mmHg
- Portal Hypertension is HVPG > 5 mmHg
- Clinical Manifestations occur at HVPG > 10 mmHg as collaterals develop
- Aim of TIPSS is to reduce HVPG to < 12mmHg

21

Patient Selection

Significant evidence

Refractory ascites

Variceal bleeding

Limited evidence

Portal hypertensive gastropathy

Gastric antral vascular ectasia

Refractory hepatic hydrothorax

Hepatorenal syndrome

Budd-Chiari syndrome

Hepatic veno-occlusive disease

Hepatopulmonary syndrome




Conduct of Anaesthesia

- Pre-procedure workup
- Remote site anaesthesia
- Unfamiliarity amongst anaesthetic and theatre staff
- Complicated patients with multiple comorbidities
- Risk of post-procedure complications

Anaesthetic Technique

- Sedation or General Anaesthesia
- Likely GA
- Induction in theatre with transfers or in radiology suite
- Difficult IV access
- Tracheal Intubation
- Arterial Line
- Additional Pressure Transducer to measure HVPG
- TIVA or Volatile with muscle relaxant
- Depth of Anaesthesia Monitoring

25



Post-Procedure Concerns

- Haemodynamic instability following any blood loss
- Heart Failure in susceptible groups
- Haemolytic anaemia between days 7 and 14
- Encephalopathy in 20% of patients
- Contrast nephropathy
- Gram Negative Sepsis
- · Stent occlusion, thrombosis or dislodgement

27

CRQ - Question One

- a) List the five components of the Child-Pugh Score (5 marks)
- Serum Albumin
- Ascites
- Bilirubin
- INR / Prothrombin Time
- Hepatic Encephalopathy

Mnemonic ABCDE:

Albumin, Bilirubin, Clotting (INR), Distension (Ascites), Encephalopathy

a) List the five components of the Child-Pugh Score (5 marks)

	Points*		
Clinical and Lab Criteria	1	2	3
Encephalopathy	None	Mild to moderate (grade 1 or 2)	Severe (grade 3 or 4)
Ascites	None	Mild to moderate (diuretic responsive)	Severe (diuretic refractory)
Bilirubin (mg/dL)	< 2	2-3	>3
Albumin (g/dL)	> 3.5	2.8-3.5	<2.8
Prothrombin time			
Seconds prolonged	<4	4-6	>6
International normalized ratio	<1.7	1.7-2.3	>2.3

Child-Turcotte-Pugh Class obtained by adding score for each parameter (total points)

Class A = 5 to 6 points (least severe liver disease)

Class B = 7 to 9 points (moderately severe liver disease)

Class C = 10 to 15 points (most severe liver disease)

29

MELD Score

Model for End-stage Liver Disease score = 6.43 + 3.78 Ln(serum total bilirubin [mg per dL]) + 11.2 Ln(International Normalized Ratio) + 9.57 Ln(serum creatinine [mg per dL])

Score	90-day mortality (%)	
≥ 40	71.3	
30 to 39	52.6	
20 to 29	19.6	
10 to 19	6.0	
≤ 9	1.9	

NOTE: Although originally developed to predict three-month mortality in patients who had undergone transjugular intrahepatic portosystemic shunt procedure, the Model for End-stage Liver Disease score is now used to prioritize patients for liver transplant. Model for End-stage Liver Disease score calculators can be found at http://www.thedrugmonitor.com/meld.html and http://www.mdcalc.com/meld-score-model-for-end-stage-liver-disease-12-and-older.

b) List four common causes of portal hypertension (4 marks)

Pre-hepatic

Portal vein thrombosis

Splenic vein thrombosis

Intra-hepatic

Alcoholic cirrhosis

Non-alcoholic fatty liver disease (NAFLD)

Viral hepatitis B and C

Drugs (e.g. methotrexate)

Wilson's disease

Haemochromatosis

Primary biliary cirrhosis

Sarcoidosis

Polycystic liver disease

Idiopathic fibrosis

Post-hepatic

Hepatic venous obstruction

Budd-Chiari syndrome

31

CRQ - Question One

- c) List the two indications, both consequences of portal hypertension, for TIPS procedure with the most evidence of benefit (2 marks)
- Refractory Ascites

Diuretic-resistant ascites which requires frequent paracentesis

Variceal Bleeding

TIPSS can be used to control haemorrhage from oesophageal and gastric varices, and to prevent recurrence once initial control has been established

c) List the two indications, both consequences of portal hypertension, for TIPS procedure with the most evidence of benefit (2 marks)

Indications with limited evidence of benefit following TIPSS:

- Portal hypertensive gastropathy
- Gastric antral vascular ectasia
- Refractory hepatic hydrothorax
- Hepatorenal syndrome
- Budd–Chiari syndrome
- Hepatic veno-occlusive disease
- Hepatopulmonary syndrome

33

CRQ - Question One

- d) Which blood vessel is most frequently punctured percutaneously as part of the TIPS procedure? (1 mark)
- Right Internal Jugular Vein

- e) Between which two vessels is a communication made during the TIPS procedure? (2 marks)
- Hepatic Vein
- Hepatic Portal Vein

35

CRQ - Question One

f) What will be the effect on the following immediately following TIPS? (2 marks)

• Preload: Increase

Pulmonary artery pressure: Increase

g) List four contraindications to performing a TIPS procedure (4 marks)

Absolute contraindications

- Heart failure
- Severe tricuspid regurgitation
- Severe pulmonary hypertension (mean pulmonary pressure >45 mm Hg)
- Multiple hepatic cysts
- Sepsis
- Biliary obstruction

37

CRQ - Question One

g) List four contraindications to performing a TIPS procedure (4 marks)

Relative contraindications

- Hepatocellular carcinoma
- Obstruction of all hepatic veins
- Portal vein thrombosis
- Severe coagulopathy
- Thrombocytopenia (platelet count < 20 × 10⁹ litre⁻¹)
- Prior hepatic encephalopathy
- Moderate pulmonary hypertension